5
Total investments
1
Early stage
0
Mid stage
0
Late stage
24y
Years active
Portfolio
1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
2002
We are your partner of choice in Europe for precision diagnostic solutions for positron emission tomography (PET) imaging – a cornerstone of personalized nuclear medicine. Our core mission is to develop, manufacture, test, and timely supply radiopharmaceutical products for patients in need, with a primary focus on oncology, while expanding our network and expertise into other disease areas, such as neurology, as we continue to unlock the potential of molecular imaging in nuclear medicine.
Experience · 6 entries
All (6)
Investments (5)
Founder (1)
Board (5)
2020
Non Executive Board Member
Jun 2020
About us
With more than 65 years of experience in delivering life-changing science, Lantheus is committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease. Lantheus is headquartered in Massachusetts and has offices in New Jersey, Canada and Sweden.
2019
Non Executive Board Member
Nov 2019
Progenics is now a Lantheus company.
Follow us at https://www.linkedin.com/company/lantheus-medical-imaging/
2018
Y
YMABS
Non Executive Board Member
Dec 2018
2014
I
IEL UK
Board Member
2014
2002
COO Group/co founder
2002
We are your partner of choice in Europe for precision diagnostic solutions for positron emission tomography (PET) imaging – a cornerstone of personalized nuclear medicine. Our core mission is to develop, manufacture, test, and timely supply radiopharmaceutical products for patients in need, with a primary focus on oncology, while expanding our network and expertise into other disease areas, such as neurology, as we continue to unlock the potential of molecular imaging in nuclear medicine.
Show all 6 entries ↓
Investment activity
2002–2020 · 5 investments
Recent (last 2 years)Earlier